CEO David Campbell (Janux)
Fresh off $1B+ Merck deal, Janux locks down first private fundraise for its T cell engagers
Janux Therapeutics had kept a relatively low profile since being founded back in 2017 but burst onto the scene late last year when Merck …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
